Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Flow Cytometric Cell Selection
Bone Marrow
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Specimen Type: Bone marrow aspirate
Container/Tube: Lavender or pink top (EDTA) or yellow top (ACD)
Specimen Volume: 2 mL
Collection Instructions:
1. Minimum plasma cell percentage is 5%.
2. Invert several times to mix bone marrow.
3. Send bone marrow specimen in original tube. Do not aliquot.
4. Label specimen as bone marrow.
5. Fresh specimen is required for this test, as testing is performed on sorted cells.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerate
2 mL
Gross hemolysis | Reject |
Gross lipemia | OK |
Fully clotted | Reject |
Bone marrow biopsies Slides Paraffin shavings Frozen tissues Paraffin-embedded tissues Paraffin-embedded bone marrow aspirates Extracted DNA | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Bone Marrow | Ambient | 4 days |
Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel
Testing allows for further risk categorization of multiple myeloma (MM) through identifying additional abnormalities of prognostic and, potentially, therapeutic value. Application of targeted next-generation sequencing-based analysis is a useful adjunct to the standard evaluation of MM patients at diagnosis and relapse.
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Not applicable
Correlation with clinical, histopathologic, and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.
No significant cautionary statements
1. Walker BA, Boyle EM, Wardell CP, et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015;33(33):3911-3920
2. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12(5):335-348
3. Kortuem KM, Braggio E, Bruins L, et al. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016;6(2):e397
4. Kortuem KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226-1233
Selection of plasma cells using fluorescence-activated cell sorting is the most direct and robust method of obtaining relatively pure plasma cell populations for molecular assessment. This, in turn, augments the ability to identify key mutations and subclonal variants of possible clinical value without dilution effects from non-tumor cell DNA.(Instruction manual: BD FACSMelody Cell Sorter User's Guide. Revision 3. BD Biosciences; 03/2020)
Monday through Saturday
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.
88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CSPMM | NGPCM Pre-Analysis Cell Sorting, BM | No LOINC Needed |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
618627 | NGPCM Pre-Analysis Cell Sort | No LOINC Needed |
618630 | Final Diagnosis | 22637-3 |